Video

Kathleen N. Moore Discusses New PARP Inhibitors for Ovarian Cancer

Author(s):

Kathleen N. Moore M.D.
Conference|SGO Annual Meeting on Women's Cancer

Kathleen N. Moore, M.D., assistant professor, Stephenson Cancer Center, The University of Oklahoma, discusses developing new PARP inhibitors for patients with ovarian cancer. These new drugs may meaningfully prolong survival from a couple months to potentially years.

Kathleen N. Moore, M.D., assistant professor, Stephenson Cancer Center, The University of Oklahoma, discusses developing new PARP inhibitors for patients with ovarian cancer. These new drugs may meaningfully prolong survival from a couple months to potentially years.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Image of woman with text.
Enabling patients to generate CAR T-cells internally could cut kidney cancer therapy costs, explained Dr. Wayne Marasco of Dana-Farber Cancer Institute.
Kidney Cancer Research Embraces Biology-Driven Precision Approach
Related Content
PD-1 treatment may help by shifting certain immune cells to fight diseases like kidney cancer: © stock.adobe.com.
August 8th 2025

Key Immune Cells Linked to Better Kidney Cancer Outcomes

Ashley Chan
cancer horizons logo: a white microphone on a navy blue background
August 8th 2025

Oncology Approvals, Psychological Outcomes for Survivors and an Ovarian Cancer Vaccine

Alex Biese Brielle Benyon
Adding casdatifan to Cabometyx showed encouraging activity and in previously treated ccRCC: © stock.adobe.com.
August 8th 2025

Welireg Plus Cabometyx Shows Tumor Control in Kidney Cancer Trial

Tim Cortese
cancer horizons image for podcast
August 8th 2025

Conference Highlights from the 2023 ASH Annual Meeting

Brielle Benyon Alex Biese
Stereotactic body radiotherapy costs less and has shown better safety compared with immunotherapy and tyrosine kinase inhibitors in patients kidney cancer: © stock.adobe.com
August 8th 2025

Metastasis-Directed Radiotherapy Shows Improved Kidney Cancer Outcomes

Tim Cortese
Image of kidney.
August 8th 2025

Welireg Improves Quality-Adjusted Survival Time in Advanced RCC

Russ Conroy